Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|9|28|2349-2365

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.9, Iss.28, 2003-01, pp. : 2349-2365

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of endothelin receptor antagonists as potential therapeutic agents

By Ergul Adviye  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 1, 2003-01 ,pp. : 33-44

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of protease-activated receptor-1 antagonists

By Derian Claudia K   Maryanoff Bruce E   Zhang Han-Cheng   Andrade-Gordon Patricia  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 2, 2003-02 ,pp. : 209-221

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule Antagonists of the CXCR2 and CXCR1 Chemokine Receptors as Therapeutic Agents for the Treatment of Inflammatory Diseases

By  

Current Topics in Medicinal Chemistry, Vol. 6, Iss. 13, 2006-01 ,pp. : 1345-1352

Bentham Science Publishers

Access to resources Recommend Favorite

Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases

By  

Current Pharmaceutical Design, Vol. 10, Iss. 22, 2004-08 ,pp. : 2769-2778

Bentham Science Publishers

Access to resources Recommend Favorite

The Development of Cytokine Receptor Antagonists as Potential Therapeutic Agents for the Myeloproliferative Disorders

By  

Current Pharmaceutical Design, Vol. 8, Iss. 5, 2002-03 ,pp. : 357-368

Bentham Science Publishers

Access to resources Recommend Favorite